Barclays on Teva Pharma (TEVA) Amid 1.5pct Drop: '<$30 as a buy-the-dip oppty'
Tweet Send to a Friend
Barclays analyst Glen Santangelo reiterated an Overweight rating and $38.00 price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
